Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00006459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.
Study identification
- NCT ID
- NCT00006459
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2000
- Primary completion
- Not listed
- Completion
- Sep 30, 2005
- Last update posted
- Jun 6, 2012
2000 – 2005
United States locations
- U.S. sites
- 31
- U.S. states
- 21
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Cancer Institute of Huntsville | Huntsville | Alabama | 35801 | — |
| Little Rock Hematology-Oncology Associates | Little Rock | Arkansas | 72205 | — |
| Pacific Coast Hematology/Oncology Medical Group | Fountain Valley | California | 92708 | — |
| Office of Alex J.P. Makalinao | Los Angeles | California | 90045 | — |
| Hematology/Oncology Group | Santa Rosa | California | 95403 | — |
| University of Colorado Cancer Center | Denver | Colorado | 80010 | — |
| Danbury Internal Medicine | Danbury | Connecticut | 06810 | — |
| Comprehensive Cancer Care Specialists of Boca Raton | Boca Raton | Florida | 33428 | — |
| Mercy Hospital | Miami | Florida | 33133 | — |
| Mountain States Tumor Institute | Boise | Idaho | 83712 | — |
| Memorial Medical Center | Springfield | Illinois | 62781 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Indiana Community Cancer Care, Inc. | Indianapolis | Indiana | 46202 | — |
| Cancer Health Associates | Michigan City | Indiana | 46360 | — |
| North Mississippi Hematology and Oncology Associates, Ltd. | Tupelo | Mississippi | 38801 | — |
| St. John's Mercy Medical Center | St Louis | Missouri | 63141 | — |
| APN-IMPATH Research Corporation | Fort Lee | New Jersey | 07024 | — |
| Overlook Hospital | Summit | New Jersey | 07902-0220 | — |
| HemOnCare, P.C. | Brooklyn | New York | 11235 | — |
| Interlakes Oncology/Hematology PC | Rochester | New York | 14623 | — |
| N.W. Carolina Oncology & Hematology, P.A. | Hickory | North Carolina | 28603 | — |
| Oklahoma Oncology Inc. | Tulsa | Oklahoma | 74104 | — |
| Rittenhouse Hematology/Oncology | Philadelphia | Pennsylvania | 19146 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29201 | — |
| Office Of C. Michael Jones | Germantown | Tennessee | 38138 | — |
| Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group | Memphis | Tennessee | 38119 | — |
| University of Tennessee, Memphis | Memphis | Tennessee | 38163 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| Southwest Regional Cancer Center | Austin | Texas | 78705 | — |
| Intermountain Hematology/Oncology Associates, Inc. | Salt Lake City | Utah | 84124 | — |
| Northern Virginia Oncology Group, P.C. | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00006459 live on ClinicalTrials.gov.